FMP
Aug 22, 2025 11:00 AM - Andrew Wynn
Image credit: Google Images
Bridgeline Digital, Inc. (NASDAQ:BLIN) is a company that provides digital engagement solutions, helping businesses optimize their online presence and customer interactions. Despite its innovative offerings, BLIN faces challenges in capital efficiency, as indicated by its financial metrics. The company's ROIC is -21.51%, which is significantly lower than its WACC of 7.47%. This negative ROIC suggests that BLIN is not generating enough returns to cover its cost of capital.
In comparison to its peers, BLIN's ROIC to WACC ratio of -2.88 is more favorable than some but still indicates inefficiency. Marin Software Incorporated (MRIN) has a ROIC of -71.72% and a WACC of 5.59%, resulting in a ROIC to WACC ratio of -12.84. This shows that MRIN is struggling even more than BLIN in terms of capital efficiency.
Verb Technology Company, Inc. (VERB) also faces challenges with a ROIC of -56.03% and a WACC of 7.79%, leading to a ROIC to WACC ratio of -7.19. This indicates that VERB, like BLIN, is not effectively using its capital to generate returns. NeuroMetrix, Inc. (NURO) has a ROIC of -61.36% and a WACC of 12.56%, resulting in a ROIC to WACC ratio of -4.89, further highlighting the difficulties faced by these companies.
Carver Bancorp, Inc. (CARV) stands out among the peers with a ROIC of -1.81% and a WACC of 42.08%, leading to a ROIC to WACC ratio of -0.04. Although still negative, CARV's ratio is the least negative, suggesting it is closer to covering its cost of capital compared to the others. This positions CARV as having the highest potential for improvement in capital efficiency among the group.
Aug 22, 2025 7:00 AM - Danny Green
Stifel Financial Corp (NYSE:SF) is a financial services company that provides a range of services including investment banking, wealth management, and brokerage services. It operates primarily in the United States and serves individual investors, corporations, and institutions. Stifel competes with ...
Aug 22, 2025 7:00 AM - Danny Green
MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes. The company's flagship product, Afrezza, is an inhalable insulin used to control blood sugar levels in ...